Recent success for targeted therapies against immune checkpoints such as CTLA-4, PD-1 (PDCD1), and PD-L1 (CD274) [38,39] led us to characterize the immune microenvironment in HCC according to ARID1A-low and -high subtypes. This evidence concerns the gene ARID1A and hepatocellular carcinoma.